Patent intelligence · US
US 10135517
Relay link HARQ operation
Relay link HARQ operation
Patent details — US 10135517
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 20, 2018
- Expiration
- Nov 15, 2038
- Applicant
- BlackBerry Limited
- Claims
- 20
- CPC classes
- A61K, A61K31/00, A61K31/343, A61K45/06
Quick answer
US 10135517 (Relay link HARQ operation) is held by BlackBerry Limited. Status: granted. Granted Nov 20, 2018. Expires Nov 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BlackBerry Limited
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/00, A61K31/343, A61K45/06
More from BlackBerry Limited
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 10135517?
US 10135517 (Relay link HARQ operation) is held by BlackBerry Limited. Status: granted. Granted Nov 20, 2018. Expires Nov 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10135517?
BlackBerry Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 10135517 expire?
Our index shows an expiration date of Nov 15, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.